UNICHEMLABNSEUnichem Laboratories Limited· PharmaceuticalsMinimalNeutral
Announced Sat, 23 May · 22:28 IST

Unichem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

UNICHEMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.7%1-day move
₹372.60
prior close
₹361.05
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-0.9-1.0-0.8-4.7-5.2-6.1-8.9-1.8-0.9+19.8+16.1+45.0
Up moveDown movePending
AI summary

Unichem Laboratories published its Q4 FY26 and full year FY26 financial results in newspapers on May 23, 2026. Consolidated results show total income of Rs. 575.12 crore for Q4 and Rs. 2,201.85 crore for full year FY26, with consolidated net profit after tax of Rs. 10.91 crore for Q4 and Rs. 252.84 crore for the year. Full year EPS stands at Rs. 35.91 per share. Standalone Q4 showed a loss of Rs. 15.39 crore despite revenue of Rs. 356.24 crore, while full year standalone revenue was Rs. 1,412.29 crore with net profit of Rs. 158.94 crore. The EU fine of Euro 19.55 million against subsidiary Niche Generics was fully settled during the year, with the company recognizing a provision of Euro 13.96 million in FY24 and recording interest in FY26 under exceptional items. The company also recorded a gain of Rs. 1.99 crore from the sale of hpca Laboratories in April 2025.

Likely market impact

The consolidated results show healthy full-year profitability with strong EPS, though Q4 standalone performance was weak. Settlement of the EU regulatory matter removes uncertainty. Shareholders can expect continued focus on subsidiary contributions to overall group performance.